{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:51:54Z","timestamp":1791118314543,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/hjh.0b013e328364abd6","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:51:34Z","timestamp":1380322294000},"page":"2309-2319","source":"Crossref","is-referenced-by-count":19,"title":["Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure"],"prefix":"10.1097","volume":"31","author":[{"given":"Paloma","family":"Mu\u00f1oz-Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ortega-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Caro-Vadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Casanueva-Eliceiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Aragoncillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Egido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Fern\u00e1ndez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcenombre","family":"G\u00f3mez-Garre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-29-20210208","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/hrt.2003.025312","article-title":"Aldosterone blockade in cardiovascular disease.","volume":"90","author":"Struthers","year":"2004","journal-title":"Heart"},{"key":"R2-29-20210208","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","article-title":"Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.","volume":"7","author":"Nappi","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R3-29-20210208","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"R4-29-20210208","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.hdx.0000089783.30450.cb","article-title":"Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.","volume":"5","author":"Moore","year":"2003","journal-title":"Heart Dis"},{"key":"R5-29-20210208","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1358\/dot.2008.44.7.1221662","article-title":"Diastolic dysfunction: a link between hypertension and heart failure.","volume":"44","author":"Lalande","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"R6-29-20210208","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1748-1716.2008.01881.x","article-title":"Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.","volume":"194","author":"Graham","year":"2008","journal-title":"Acta Physiol (Oxf)"},{"key":"R7-29-20210208","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjhf\/hfq101","article-title":"Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction.","volume":"12","author":"Gomez-Garre","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R8-29-20210208","first-page":"H228","article-title":"Plasma renin activity in heart failure-prone SHHFMcc-facp rats.","volume":"273","author":"Holycross","year":"1997","journal-title":"Am J Physiol"},{"key":"R9-29-20210208","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/0735-1097(94)90390-5","article-title":"Assessment of left ventricular function by the midwall fractional shorteningend-systolic stress relation in human hypertension.","volume":"23","author":"de Simone","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"R10-29-20210208","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejheart.2005.06.002","article-title":"Activation of peroxisome proliferator-activated receptor- and - in auricular tissue from patients with human failing heart due to ischemic cardiomyopathy.","volume":"8","author":"Gomez-Garre","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"R11-29-20210208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1009857403356","article-title":"The extracellular matrix and the cytoskeleton in heart hypertrophy and failure.","volume":"5","author":"Jane-Lise","year":"2000","journal-title":"Heart Fail Rev"},{"key":"R12-29-20210208","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/j.1755-5922.2011.00276.x","article-title":"Matricellular proteins: new molecular targets to prevent heart failure.","volume":"30","author":"Okamoto","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"R13-29-20210208","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","article-title":"Introduction to NF-B: players, pathways, perspectives.","volume":"25","author":"Gilmore","year":"2006","journal-title":"Oncogene"},{"key":"R14-29-20210208","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.","volume":"52","author":"Di Zhang","year":"2008","journal-title":"Hypertension"},{"key":"R15-29-20210208","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cardiores.2005.03.001","article-title":"Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.","volume":"67","author":"Fraccarollo","year":"2005","journal-title":"Cardiovasc Res"},{"key":"R16-29-20210208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2004.02.010","article-title":"Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.","volume":"10","author":"Masson","year":"2004","journal-title":"J Card Fail"},{"key":"R17-29-20210208","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/00005344-200306000-00002","article-title":"Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.","volume":"41","author":"Kambara","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"R18-29-20210208","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"R19-29-20210208","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","article-title":"Rationale and design of the aldosterone receptor blockade in diastolic heart failure trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).","volume":"12","author":"Edelmann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R20-29-20210208","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"R21-29-20210208","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.HYP.0000161873.27088.4c","article-title":"Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure.","volume":"45","author":"Rysa","year":"2005","journal-title":"Hypertension"},{"issue":"Suppl N","key":"R22-29-20210208","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/eurheartj\/16.suppl_N.19","article-title":"The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure.","volume":"16","author":"Boluyt","year":"1995","journal-title":"Eur Heart J"},{"key":"R23-29-20210208","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.amjhyper.2007.01.016","article-title":"Matriz metalloprotease activity is enhanced in the compensated but not in the decompesated phase of pressure overload hypertrophy.","volume":"20","author":"Tozzi","year":"2007","journal-title":"Am J Hypertens"},{"key":"R24-29-20210208","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/01.CIR.103.18.2303","article-title":"Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.","volume":"103","author":"Peterson","year":"2001","journal-title":"Circulation"},{"key":"R25-29-20210208","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/01.CIR.0000125741.88712.77","article-title":"Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor.","volume":"109","author":"Sakata","year":"2004","journal-title":"Circulation"},{"key":"R26-29-20210208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1248\/bpb.34.61","article-title":"Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats.","volume":"34","author":"Hori","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"R27-29-20210208","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.fjc.0000211791.22411.0d","article-title":"Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure.","volume":"47","author":"Saka","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"R28-29-20210208","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1054\/jcaf.2002.129282","article-title":"Signaling pathways activated by vasoactive peptides in the cardiac myocyte and their role in myocardial pathologies.","volume":"8","author":"Sugden","year":"2002","journal-title":"J Card Fail"},{"key":"R29-29-20210208","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.","volume":"43","author":"Lopez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R30-29-20210208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12079-009-0070-6","article-title":"Thrombospondins in the heart: potential functions in cardiac remodeling.","volume":"3","author":"Schellings","year":"2009","journal-title":"J Cell Commun Signal"},{"key":"R31-29-20210208","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.1415","article-title":"Tenascins: regulation and putative functions during pathological stress.","volume":"200","author":"Chiquet-Ehrismann","year":"2003","journal-title":"J Pathol"},{"key":"R32-29-20210208","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.transproceed.2009.06.009","article-title":"Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.","volume":"41","author":"Batlle","year":"2009","journal-title":"Transplant Proc"},{"key":"R33-29-20210208","doi-asserted-by":"crossref","first-page":"H2251","DOI":"10.1152\/ajpheart.01104.2010","article-title":"Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload.","volume":"300","author":"Chen","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R34-29-20210208","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1084\/jem.20081244","article-title":"Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction.","volume":"206","author":"Schellings","year":"2009","journal-title":"J Exp Med"},{"key":"R35-29-20210208","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.108.773424","article-title":"Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in postsynthetic procollagen processing.","volume":"119","author":"Bradshaw","year":"2009","journal-title":"Circulation"},{"key":"R36-29-20210208","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","article-title":"Inflammation as a therapeutic target in heart failure A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.","volume":"11","author":"Heymans","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R37-29-20210208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FJC.0b013e318033dfd4","article-title":"Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.","volume":"49","author":"Nishioka","year":"2007","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0b013e328364abd6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:41:59Z","timestamp":1621885319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201311000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e328364abd6","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}